FOXA1 was shown to be required for all ERbinding sites in models of ER+ breast cancer, and was also shown to berequired for ER binding and growth of endocrine-resistant breast cancer cell linemodels (45). This evidence concerns the gene FOXA1 and breast carcinoma.